Heart failure & cardiomyopathies

Dapagliflozin for Renal Protection in Heart Transplant Recipients: A Randomized Clinical Trial

CirculationPublished multicenter, double-blind, randomized, placebo-controlled trial

Primary result · Slope of the eGFR (change in eGFR from 2 weeks to 12 months after treatment initiation)Result — go to the resultBetween-group difference 1.7 mL/min/1.73 m ² 95% CI 0.1–3.3

Authors' conclusion

In heart transplant recipients, dapagliflozin, compared with placebo, improved the slope of the eGFR from 2 weeks to 12 months of treatment.

Study context

Population
Adult heart transplant recipients with an estimated glomerular filtration rate (eGFR) ≥25 mL/min/1.73 m ² at least one year after transplantationrandomized, 424 patients with at least one eGFR measurement after baseline in the full analysis set
Participants
430 recipients
Comparison
Dapagliflozin 10 mg vs matching placebo once daily
  • Dapagliflozinn = 217
  • Placebon = 213
Primary endpoint
Slope of the eGFR (change in eGFR from 2 weeks to 12 months after treatment initiation)
Follow-up
From 2 weeks after treatment initiation to the end of the 12-month blinded treatment period
Methodological detailssix heart transplant centers in Northern Europe, 1:1 randomization
  • Six heart transplant centers in Northern Europe
  • 1:1 randomization

Primary result

As reported in the abstract

Slope of the eGFR (change in eGFR from 2 weeks to 12 months after treatment initiation)

Between-group difference

1.7 mL/min/1.73 m ²

95% CI 0.1–3.3

P = 0.03

Change by group

Dapagliflozin

2.0

change · 95% CI 1.0–3.1 · mL/min/1.73 m²

Placebo

0.3

change · 95% CI −0.8 to 1.4 · mL/min/1.73 m²

Dapagliflozinvs placebo
between-group difference 1.7 mL/min/1.73 m ² (95% CI 0.1–3.3); P = 0.03

Further findings

Baseline characteristics (full analysis set)

Mean age
53 ± 14 years
Baseline eGFR
67 ± 22 mL/min/1.73 m 2
Median time from transplantation
7 (3 - 13) years

Original publication

Dapagliflozin for Renal Protection in Heart Transplant Recipients: A Randomized Clinical Trial. Circulation. Published 8 November 2026. doi:10.1161/circulationaha.126.083760

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.